Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, noviembre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Cue Biopharma Inc
CUE
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$4.15
-0.35
-7.78%
al cierre: Nov 20, 4:00 PM EST
$4.20
0.05
1.2%
After hour: 7:55 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Ganancias:
Los beneficios de Q3 2026 se publicaron el lun nov 16th, después del cierre del mercado
Cue Biopharma Financials
Cue Biopharma (CUE) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Dow Falls Over 300 Points; Nvidia Posts Upbeat Earnings
U.S. stocks fell as the Dow slid 300+ points; Nvidia beat Q3 estimates, while energy, commodities and European markets declined.
Avi Kapoor
Dow Falls Over 200 Points; US Retail Sales Rise 0.2% In October
U.S. stocks were mixed as the Dow fell 200+ points; retail sales rose 0.2%, oil gained 1.5%, and SLS surged 177%.
Avi Kapoor
PRO
Cue Biopharma Q3 EPS $(4.74) Misses $(2.24) Estimate, Sales $132.000K Miss $1.033M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(4.74) per share which missed the analyst consensus estimate of $(2.24) by 111.61 percent. This is a 113.51 percent decrease over losses of $(2.22) per share from
Benzinga Newsdesk
PRO
Cue Biopharma Q2 EPS $(24.14) Misses $(1.69) Estimate, Sales $7.877M Beat $3.000M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(24.14) per share which missed the analyst consensus estimate of $(1.69) by 1328.4 percent. This is a 794.07 percent decrease over losses of $(2.70) per share
Benzinga Newsdesk
PRO
Cue Biopharma Q1 EPS $(1.08) Misses $(0.10) Estimate, Sales $5.686M Beat $1.875M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.10) by 1100 percent. This is a 78.18 percent increase over losses of $(4.95) per share from the
Benzinga Newsdesk
PRO
Cue Biopharma Q4 EPS $0.01 Beats $(0.10) Estimate, Sales $21.942M Up From $1.576M Prior Year
Cue Biopharma (NASDAQ:CUE) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.10) by 110 percent. This is a 107.69 percent increase over losses of $(0.13) per share from the
Benzinga Newsdesk